Funding for this research was provided by:
Asahi Kasei Pharma Corporation
Article History
Received: 20 May 2020
Accepted: 17 October 2020
First Online: 19 November 2020
Compliance with ethical standards
:
: I.Tanaka has received speaking fees, and/or honoraria from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, MSD, Ono Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, Taisho Pharma, and Teijin Pharma. Y. Tanaka has received speaking fees and/or honoraria from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical, Teijin Pharma, and YL Biologics and has received research grants from Asahi Kasei Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Sanofi, Takeda Pharmaceutical, and UCB Japan. S. Soen has received consulting fees, speaking fees, and/or honoraria from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, MSD, Ono Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, and Teijin Pharma. H. Oshima has no conflicts of interest.